1. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in Newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800–4.
2. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.
3. Abikhzer G, Gourevich K, Kagna O, Israel O, Frenkel A, Keidar Z. Whole-body bone SPECT in breast cancer patients: the future bone scan protocol? Nucl Med Commun. 2016;37(3):247–53.
4. Romer W, Nomayr A, Uder M, Bautz W, Torsten K. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47(7):1102–6.
5. Ichikawa H, Miwa K, Okuda K, Shibutani T, Kato T, Nagaki A, et al. Current state of bone scintigraphy protocols and practice in Japan. Asia Ocean J Nucl Med Biol. 2020;8(2):116–22.